Wave's WVE-007 Silences Activin E by 88%, Sustained for 7.5 Months in Phase I

In an obesity market dominated by weekly injectables with high discontinuation rates, Wave's WVE-007 offers a differentiated mechanism—siRNA-mediated silencing of Activin E. Phase I data revealed a robust and sustained pharmacodynamic effect, with 88% serum Activin E reduction lasting over 7.5 months, and a 16.5% improvement in visceral fat-to-muscle ratio that outperforms semaglutide in an indirect comparison. The ongoing INLIGHT Phase IIa trial will test whether this translates into meaningful clinical benefit for patients with class II/III obesity.

Wave Life Sciences’ second-quarter 2026 earnings call, held on July 30, laid bare both the promise and the cost of advancing a next-generation RNA editing platform. Revenue plummeted to $2.3 million from $8.7 million in the prior year quarter, a 74% decline driven almost entirely by the timing of milestones in its GSK collaboration. Yet the company’s cash reserves, standing at $490.6 million as of June 30, 2026, caught the market’s attention: management expects this war chest to fund operations into the third quarter of 2028, well past the anticipated readouts of multiple clinical trials. The message was clear—near-term volatility in top-line revenue is less important than the clinical validation ahead.

“

Research and development expenses rose to $51.3 million from $43.5 million a year ago, while general and administrative costs swelled to $24.8 million from $18 million.

The quarter’s financials reflected the ramp-up in investment. Research and development expenses rose to $51.3 million from $43.5 million a year ago, while general and administrative costs swelled to $24.8 million from $18 million. Both increases were attributed to the initiation of the INLIGHT Phase IIa trial for WVE-007, an siRNA candidate targeting Activin E for obesity, and the broader RNA editing pipeline that includes WVE-006 for alpha-1 antitrypsin deficiency (AATD). With a net loss of $69.4 million—up from $50.5 million in Q2 2025—the company’s burn rate is now running at over $270 million annually. But with zero debt and nearly half a billion dollars on hand, the balance sheet provides a substantial cushion.

The star of the call was undoubtedly WVE-007. The company unveiled Phase I data showing that a single dose of its GalNAc-conjugated siRNA reduced serum Activin E levels by up to 88%, with the silencing effect sustained for at least 7.5 months. This durability is a key differentiator in an obesity market where the dominant GLP-1 receptor agonists must be administered weekly—or daily in oral form—and still see a staggering 70% discontinuation rate within the first year. Even more tantalizing were the body composition results: WVE-007 improved the visceral fat-to-muscle ratio (VMR) by 16.5% after a single dose, compared to 12.2% reported for weekly semaglutide in the BELIEVE study. While cross-trial comparisons are inherently limited, the implication is that siRNA-mediated Activin E silencing may preserve muscle mass while preferentially reducing harmful visceral fat—a holy grail in obesity pharmacotherapy.

Wave is not just betting on a better mousetrap; it is pursuing a patient population that is both large and poorly served. The INLIGHT Phase IIa trial is enrolling 160 individuals across four cohorts of 40 patients each, all with BMIs between 35 and 50 (class II–III obesity), split by type 2 diabetes status. This design underscores a strategy to target those where current therapies often fall short—patients with severe obesity who may have comorbidities or have cycled off GLP-1s. The addressable market is immense: 175 million people in the U.S. and Europe alone live with obesity, and many are in dire need of durable, disease-modifying treatments with better adherence profiles.